These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10721166)

  • 1. [Practice guidelines--disorders of lipid metabolism. From recommendations to therapy of disorders of lipid metabolism by the Drug Committee of the German Medical Society. Drug Committee of the German Medical Society].
    Z Arztl Fortbild Qualitatssich; 2000 Jan; 94(1):61-4. PubMed ID: 10721166
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement in current approaches to lipid lowering.
    Ansell BJ
    Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952
    [No Abstract]   [Full Text] [Related]  

  • 4. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E; Jiménez Navarro M
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lipid metabolism disorders: diagnosis and treatment. 4: Drug therapy and dietary recommendations. National Cholesterin-Initiative].
    Fortschr Med; 1991 May; 109(16):344-7. PubMed ID: 1855762
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 8. [New drug against lipid disorders. HDL level rises 30%].
    MMW Fortschr Med; 2003 Sep; 145(39):51. PubMed ID: 14649076
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of coronary arteriosclerosis depending on the nature of lipid metabolism disorders].
    Anisimov VE; Semavin IE
    Klin Med (Mosk); 1975 Jul; 53(7):66-9. PubMed ID: 1206996
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipids and their role in coronary heart disease: what they do and how to manage them.
    Pradka LR
    Nurs Clin North Am; 2000 Dec; 35(4):981-91. PubMed ID: 11072283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Adv Intern Med; 1997; 42():1-38. PubMed ID: 9048115
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cost-benefit analysis of the therapy of lipid metabolism disorders].
    Karádi I
    Orv Hetil; 1996 May; 137(21):1164. PubMed ID: 8757110
    [No Abstract]   [Full Text] [Related]  

  • 13. Choosing the most appropriate therapy for lipid disorders.
    Simons LA
    Aust Fam Physician; 2000 Mar; 29(3):199-203. PubMed ID: 10785984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
    Mosca LJ
    Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
    Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
    CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
    [No Abstract]   [Full Text] [Related]  

  • 16. [Guidelines for lipid-lowering therapy. Results of the 2d Consensus Conference of the European Atherosclerosis Society. Press conference. London, 6 May 1988].
    Fortschr Med Suppl; 1988; 46():1-22. PubMed ID: 2905324
    [No Abstract]   [Full Text] [Related]  

  • 17. [Role of lipemia-lowering agents in the secondary prevention of myocardial infarct].
    Tullio D
    Clin Ter; 1986 Feb; 116(3):221-35. PubMed ID: 3516543
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy for dyslipidemia.
    Spellman CW
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S9-11. PubMed ID: 12572624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperlipidemia: therapeutic principles in clinical practice].
    Müller-Wieland D; Krone W
    Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.